TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
By harnessing the potential of these precision peptides, you can boost your energy, accelerate fat loss, and experience noticeable, lasting resultsall while performing at your peak and feeling your best every day
A patients injuries, medical history, and desired level of recovery inform the development of a unique TB-500 protocol within the Concierge MD framework
Without adequate carnitine, long-chain fatty acids the primary fuel source for low to moderate intensity aerobic activity cannot cross the mitochondrial membrane and cannot be oxidized for energy
